Consano Bio Raises More Than $15 Million in Oversubscribed Financing to Advance C-1101 in Chronic Painful Lumbosacral Radiculopathy (Chronic Sciatica)

Summary

Consano Bio raised more than $15 million in oversubscribed financing to fund completion of Phase 1 trial for C-1101, a potential first-in-class disease-modifying therapeutic for chronic sciatica, with clinical data expected in 1H 2027.